Insulet reported results from the EVOLUTION 2 multicenter feasibility study of its investigational fully closed-loop automated insulin delivery system for adults with type 2 diabetes, which were presented at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Barcelona. The study enrolled 24 adults in New Zealand aged 16–70 years with type 2 diabetes using insulin, and evaluated multiple algorithm versions. Using the final algorithm version with no boluses, participants achieved an average 68% time in range, representing a 24% improvement versus standard injection therapy. Time below range had a median of 0% below 70 mg/dL, and no severe hypoglycemia or diabetic ketoacidosis events were observed. Insulet said it plans to start the EVOLVE pivotal study in 2026 to support a 510(k) filing in 2027 and a commercial launch in 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insulet Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202603111601BIZWIRE_USPR_____20260311_BW660681) on March 11, 2026, and is solely responsible for the information contained therein.